Intellectual Property News & Topics - Secerna LLP

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more

HERCEPTIN

News, A to Z Feature 23/01/2025

A to Z: Drugs in Highlight: H is for HERCEPTIN®

EPO 2021

European, News 21/01/2025

Added Matter Objections at the European Patent Office (EPO)

Secerna Website Images 2025

Industry news, News 20/01/2025

Thatchers vs Aldi: A Victory in the Battle Against Cloudy Lemon Cider Dupe

Generative AI

Industry news, News 17/01/2025

USPTO Announces AI Strategy to Empower Responsible Innovation

GILENYA

News, A to Z Feature 16/01/2025

A to Z: Drugs in Highlight: G is for GILENYA®

Jason Boakes And Sam Turton Secerna LLP (2)

News, Team news, Careers 14/01/2025

Secerna Strengthens Team with Addition of Trade Mark Attorney

Seas The Day X Secerna Linkedin Square

Events, News, Team news 13/01/2025

Seas the Day Ocean Rowing Team Visits Secerna HQ Ahead of Pacific Challenge

Secerna Website Images 2023 (67)

Events, Careers 09/01/2025

Discover Patent Law at the Durham SME Careers Fair

FERRIPROX

News, UPC, A to Z Feature 07/01/2025

A to Z: Drugs in Highlight: F is for FERRIPROX®

1 2 3 4 5 6 7 8 9 10